Dr. Mendoza is a certified medical oncology from Autonomous University of Barcelona (Spain). Dr Mendoza completed his residency in Medical Oncology at the Santa Creu i Sant Pau Hospital in Barcelona, Spain. As a physician, he has an extensive record with the treatment of bad-prognosis cancer patients with high-dose chemotherapy and bone marrow transplantation. He continued with his PhD studies in the field of immunology-oncology at the Academy of Sciences in Prague where he worked in different types of anticancer vaccines and became an expert in the field of dendritic-cell based vaccines in experimental models.
Dr. Luis Mendoza has a position of Head Team Hematology/Oncology within the Oncology Global Therapeutic Delivery Unit of IQVIA. He has served as Senior Medical and Scientific Advisor on dozens of different clinical trials in solid tumors and hematologic malignancies. He has huge experience in hem-oncology trials testing different anticancer compounds like targeted therapies, immunotherapies, oncolytic virus vaccines, antibody-drug conjugated vaccines, chemotherapies, PARP inhibitors and antiangiogenic drugs. He has a record of more than 40 phase I clinical trials. He has supported the preclinical and clinical development of anticancer drugs and has overseen several oncology and non-oncology global drug development programs.
Prior to joining IQVIA in January 2015, Dr. Luis Mendoza acquired 20+ years of hematology and oncology experience in the oncology medical practice. Dr Mendoza continues with his altruistic unpaid labour as a second-opinion consultant for physicians or cancer patients. He is author and co-author of 80+ medical and scientific publications in peer review journals and author of educational manuals in cancer.
Dr. Luis Mendoza has a position of Head Team Hematology/Oncology within the Oncology Global Therapeutic Delivery Unit of IQVIA. He has served as Senior Medical and Scientific Advisor on dozens of different clinical trials in solid tumors and hematologic malignancies. He has huge experience in hem-oncology trials testing different anticancer compounds like targeted therapies, immunotherapies, oncolytic virus vaccines, antibody-drug conjugated vaccines, chemotherapies, PARP inhibitors and antiangiogenic drugs. He has a record of more than 40 phase I clinical trials. He has supported the preclinical and clinical development of anticancer drugs and has overseen several oncology and non-oncology global drug development programs.
Prior to joining IQVIA in January 2015, Dr. Luis Mendoza acquired 20+ years of hematology and oncology experience in the oncology medical practice. Dr Mendoza continues with his altruistic unpaid labour as a second-opinion consultant for physicians or cancer patients. He is author and co-author of 80+ medical and scientific publications in peer review journals and author of educational manuals in cancer.
